Navigation Links
Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications
Date:10/24/2011

TUCSON, Ariz., Oct. 24, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm HER2 (4B5) for image analysis applications with associated VIRTUOSO software and iScan Coreo Au scanner. Ventana is now the only company with a complete workflow solution for determining HER2 (4B5) expression in breast cancer patients.

The application assists the pathologist in the detection and semi-quantitative measurement of HER2 (4B5) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue. While the pathologist is still the ultimate authority in scoring HER2 (4B5) stains, the image analysis application helps ensure consistency and objectivity in interpretation.

When used with the VENTANA PATHWAY anti-HER2 (4B5) Rabbit Monoclonal Primary Antibody, it is indicated for use as an aid in the assessment of breast cancer patients for whom HERCEPTIN (Trastuzumab) treatment is being considered. The 510(k) clearance covers all components of the workflow including the 4B5 clone, slide stainer, detection systems, software and scanner.

"The addition of the Companion Algorithm for HER2 (4B5) to the VENTANA portfolio of products gives pathologists an important tool for assessing HER2 (4B5) expression in breast cancer patients," said Dr. Steve Burnell, lifecycle leader for advanced workflow. "Ventana continues to lead the industry with its commitment to providing customers a complete, optimized solution – including stainers, reagents, scanners and digital pathology software applications - that provides accurate and efficient testing results."

Ventana also received FDA clearance for the digital read application that allows the pathologist to view HER2 (4B5) stained slides as images on a computer monitor with VIRTUOSO software and iScan Coreo Au scanner.

About Ventana Medical Systems, Inc. Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's "Smart Systems" – intuitive, integrated staining and workflow management platforms that optimize laboratory efficiencies to reduce errors – support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving personalized medicine through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com to learn more.

Ventana products are for in vitro diagnostic use for specific applications, and are research use only for other applications.

VENTANA, the VENTANA logo, PATHWAY, Companion Algorithm, VIRTUOSO and BenchMark are trademarks of Roche.

VMSI Media Relations
Jacqueline Bucher
Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody
2. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
3. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
4. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
5. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
6. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
7. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
8. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
9. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
10. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
11. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... ... Liquid Biopsy System , a fully automated benchtop system for collecting intact circulating ... is being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 ...
(Date:2/21/2017)... (PRWEB) , ... February 21, ... ... the Life -Sciences division, Treximo will pair its $200M operational capacity with ... consulting and project management in areas affecting quality and operational management. ...
(Date:2/21/2017)... -- Lexus, a returning partner of the Amgen Tour of California ... partner of the men,s and women,s events for the next five ... Tour of California will mark the start ... professional cycling teams in the world racing from Northern to ... Breakaway from Heart Disease TM Women,s Race empowered with ...
(Date:2/21/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Bioplastics & Biopolymers ... over the next decade to reach approximately $8.9 billion by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology Technology:
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
Breaking Biology News(10 mins):